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Clinical and translational medicine plays a unique and
critical role in fostering the flow of bidirectional informa-
tion between basic and clinical scientists, optimizing new
biotechnologies, improving clinical application of new
therapeutic concepts, and ultimately improving the qual-
ity of life for patients. The term “Clinical and Transla-
tional Medicine” (CMT) is defined here as “clinical
potential and application of translational research and
science to improve the understanding of mechanisms
and therapies of human diseases”, a new and important
concept for the development of disease-specific biomar-
kers and therapeutic strategies to monitor and cure
disease. Clinical and Translational Medicine as an
international open-access journal publish articles focused
on novel advances in clinical, translational, and clinically-
relevant basic science, to accelerate the transition from
preclinical research to clinical applications and the com-
munication between basic and clinical scientists. Clinical
and Translational Medicine is particularly interested in
drug discovery and development, related regulatory pro-
cesses, as well as broader topics related to public health
and relevant policies. Clinical and Translational Medi-
cine will also focus on new insights into molecular
mechanisms, clinical questions and experience, as well as
the discovery and development of personalized health-
care delivery.
Clinical and translational science has been defined as a
novel attempt to “translate remarkable scientific innova-
tions into health gains”, and is a critical and core compo-
nent of full-spectrum biomedical research [1]. Translational
research as a key word was emphasized and headlined in
the National Institutes of Health guide for Specialized Pro-
gram of Research Excellence (SPORE) grants for cancer
research [2]. Furthermore, translational science has been
defined as a two-way process to translate discoveries from
the bench into clinical application and/or the translation of
clinical findings into the understanding of molecular
mechanisms [3,4]. Given the growing impact of scientific
knowledge and discoveries on clinical practice, translational
medicine was initially described as “the marriage between
new discoveries in basic science and clinical practice” [5].
Clinical and translational medicine can be used to under-
stand the mechanisms of clinical variation between dis-
eases, pathogenesis, biomarkers, and therapies. For
example, translational medicine is involved in determining
optimal regimens to alleviate symptoms and improve qual-
ity of life. The efficacy and safety of drugs selected from
pre-clinical animal models can be translated into applicable
and therapeutic approaches for clinical trials [6].
Clinical and translational medicine plays a unique and
critical role in fostering the flow of bidirectional informa-
tion between basic and clinical scientists, optimizing new
biotechnologies, improving clinical application of new
therapeutic concepts, and ultimately improving the qual-
ity of life for patients. Clinical and translational medicine
integrates clinical research with modern methodologies
in systems and computational biology, genomics, proteo-
mics, metabolomics, pharmacomics, transcriptomics, and
high-throughput image analysis. It should also foster the
implementation of human tissue banking, and the devel-
opment of bio-banks linked to high quality clinical data
bases, for identification of clear phenotypes relevant to
stratification of patients receiving standard or experimen-
tal therapies [7,8]. Clinical and translational medicine is a
limiting factor and accelerator in the process of moving
from preclinical discovery and development to clinical
application, validating the application of new technolo-
gies in patients, and developing new strategies to improve
the quality of life for patients. It adds scientific and evi-
dence-based value to the regulations, policies, and/or
guidelines for medications, therapies, preventive
approaches, and health care delivery. Thus, there is press-
ing need for a scientific channel and platform like the
journal of Clinical and Translational Medicine to
exchange information on the development, standardiza-
tion, application, and optimization of translational
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research and science in a manner that will facilitate com-
munication between preclinical and clinical scientists.
Clinical and translational medicine should be further-
more defined and differentiated from the understanding
of other “translational” concepts, including translational
science, translational research, translational medicine, or
clinical and translational science. In contrast to these
broader approaches, clinical and translational medicine is
expected to concentrate on clinical application-oriented
translational science and research to improve the accu-
racy, efficiency and efficacy of clinical diagnoses, thera-
pies, and determination of prognoses for patients.
Clinical and translational medicine will play an important
and applicable role in monitoring and managing the mis-
alignment between the growth in research spending and
the decrease in translational productivity, as pointed out
recently by Elias Zerhouni [9]. There is great need to
exchange knowledge and experience relating to the
development of new biotechnologies, as well as to the
understanding of gene and protein function, cell and
organ dysfunction, and pathology related to clinical signs,
symptoms, findings, measures, prognosis, and therapeutic
effects. Clinical and translational research using multidi-
mensional data from both molecular biology and medi-
cine thus accelerates and shortens the process to
translate preclinical knowledge into clinical applications.
Therefore, the journal of Clinical and Translational
Medicine has the special mission and responsibility to
emphasize the clinical potential and application of new
biotechnologies, particularly with respect to regulation
and health policy.
The journal of Clinical and Translational Medicine
will stake out the future landscape of clinical and transla-
tional research, present advances in biotechnology, facili-
tate the fast-tracking of research and development,
introduce novel diagnostics and therapeutics for clinical
use, and explore the challenges and opportunities in the
post-genomic and proteomic era to develop new disci-
plines that reflect additional levels of complexity. The
journal will help clarify bioethics at the interface of bio-
technologies and clinical applications, the paradigms of
academia-industry and public-private models, and will
address the demands of maintaining and expanding the
biomedical workforce and education programs that attract
and retain clinicians and investigators. The Journal will
play an important and critical role in enhancing the
understanding of disease-specific molecular mechanisms,
and will provide information that facilitates the develop-
ment of predictive, preventive, personalized medicine,
likely to improve of patient prognoses.
The term “Clinical and Translational Medicine“ is
defined here as “clinical potential and application of
translational research and science to improve the under-
standing of mechanisms and therapies of human
diseases”, a new and important concept for the develop-
ment of disease-specific biomarkers and therapeutic
strategies to monitor and cure disease. In addition, the
Journal will encourage and foster the establishment of
standardization and consensus of biotechnological pro-
cesses applied to clinical and translational research, to
make preclinical and clinical data more comparable and
repeatable. One of the challenging issues in translating
preclinical data into clinical application is the wide var-
iation between reports due to different protocols and
often uncontrolled conditions. Clinical and Transla-
tional Medicine has the responsibility of reducing such
misalignment, establishing standardized databases, and
developing applicable consensus. The role of clinical
and translational science and research is becoming more
important than ever, as we attempt to meet the future
needs of clinical and translational medicine, to form
more global opinion leaders to bridge the gap between
understanding basic science and human disease, and to
define the content, regulation and policy of clinical and
translational medicine. Clinical and Translational
Medicine will provide a forum for the exchange of ideas
on translational skills, methodologies, definitions, proto-
cols, regulations and policies for clinical application and
improvement of health care.
Clinical and Translational Medicine is also proud to
be affiliated with the newly established International
Society of Translational Medicine (ISTM) [10] and will
be a primary publication site for clinical and translational
science and research associated with ISTM. As a non-
profit organization, ISTM is a network of clinicians and
researchers from all fields of science with an interest in
translational medicine. The partnership between the
Journal and ISTM will facilitate interdisciplinary research
across clinical medicine and translational science. Clini-
cal and Translational Medicine encourages publishing
scientific collaborations between basic scientists and
clinical investigators with the requisite skills to design
longitudinal studies and deal with regulatory and human-
protection complexities. The Journal provides a forum
for basic scientists to collaborate with clinical investiga-
tors and has the special policy that formally recognizes
more than one investigator as principal author on a pub-
lication, as has been previously suggested [11,12].
We, as editors of Clinical and Translational Medi-
cine, are delighted to welcome you to this new journal.
We thank the scientists who have already agreed to pub-
lish in the journal. In initiating the journal, we owe an
enormous debt of gratitude to our colleagues for their
encouragement, support, comments, suggestions and
contributions. With the support of our Associate Editors
and Editorial Board Members [13], we believe that Clini-
cal and Translational Medicine will be well-received
by preclinical, translational, and clinical scientists and
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will provide an important forum to improve the health-
care of humans.
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